$ARDX
ARDELYX, INC. Stock $ardx

$ardx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023015212 Filed on May 03, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$22.33M	$11.37M
YoY Change	784.13%	2329.27%
Cost Of Revenue	$3.489M	$1.537M
YoY Change	2428.26%	1708.24%
Gross Profit	$18.84M	$9.832M
YoY Change	689.11%	2467.1%
Gross Profit Margin	84.38%	86.48%
Selling, General & Admin	$27.19M	$26.80M
YoY Change	44.13%	38.6%
% of Gross Profit	144.27%	272.61%
Research & Development	$8.282M	$9.093M
YoY Change	-14.98%	2.73%
% of Gross Profit	43.95%	92.48%
Depreciation & Amortization	$639.0K	-$3.000K
YoY Change	265.14%	-101.29%
% of Gross Profit	3.39%	-0.03%
Operating Expenses	$35.47M	$35.90M
YoY Change	24.0%	27.34%
Operating Profit	-$16.62M	-$26.06M
YoY Change	-36.59%	-6.27%
Interest Expense	-$1.075M	$1.028M
YoY Change	-236.59%	37.8%
% of Operating Profit
Other Income/Expense, Net	$578.0K	$1.302M
YoY Change	725.71%	169.01%
Pretax Income	-$17.12M	-$26.76M
YoY Change	-36.43%	-4.67%
Income Tax	$0.00	$14.00K
% Of Pretax Income
Net Earnings	-$17.12M	-$26.77M
YoY Change	-36.44%	-4.62%
Net Earnings / Revenue	-76.66%	-235.49%
Basic Earnings Per Share	-$0.08	-$0.13
Diluted Earnings Per Share	-$0.08	-$0.13
COMMON SHARES
Basic Shares Outstanding	214.5M shares	206.5M shares
Diluted Shares Outstanding	215.0M shares	207.0M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$127.6M	$130.4M
YoY Change	57.48%	45.34%
Cash & Equivalents	$28.66M	$92.49M
Short-Term Investments	$97.52M	$37.89M
Other Short-Term Assets	$17.81M	$19.73M
YoY Change	-22.36%	18.58%
Inventory	$7.617M	$44.95M
Prepaid Expenses
Receivables	$9.109M	$12.12M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$162.1M	$167.0M
YoY Change	42.08%	46.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.117M	$1.102M
YoY Change	426.74%	-46.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$40.97M	$774.0K
YoY Change	734.72%	-36.97%
Total Long-Term Assets	$49.09M	$49.97M
YoY Change	180.44%	229.13%
TOTAL ASSETS
Total Short-Term Assets	$162.1M	$167.0M
Total Long-Term Assets	$49.09M	$49.97M
Total Assets	$211.2M	$217.0M
YoY Change	60.48%	67.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.294M	$10.51M
YoY Change	23.29%	109.01%
Accrued Expenses	$23.38M	$20.13M
YoY Change	29.68%	20.7%
Deferred Revenue	$5.959M	$5.545M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$27.05M	$26.88M
YoY Change	2.57%	2.83%
Total Short-Term Liabilities	$61.69M	$63.06M
YoY Change	26.67%	31.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$26.35M	$28.54M
YoY Change	-11.77%	64.23%
Total Long-Term Liabilities	$26.35M	$28.54M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$61.69M	$63.06M
Total Long-Term Liabilities	$26.35M	$28.54M
Total Liabilities	$88.04M	$91.60M
YoY Change	12.06%	40.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$824.0M	-$806.9M
YoY Change	7.31%	8.89%
Common Stock	$947.4M	$932.4M
YoY Change	15.38%	15.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$123.2M	$125.4M
YoY Change
Total Liabilities & Shareholders Equity	$211.2M	$217.0M
YoY Change	60.48%	67.7%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$17.12M	-$26.77M
YoY Change	-36.44%	-4.62%
Depreciation, Depletion And Amortization	$639.0K	-$3.000K
YoY Change	265.14%	-101.29%
Cash From Operating Activities	-$14.74M	-$44.80M
YoY Change	-52.89%	62.18%
INVESTING ACTIVITIES
Capital Expenditures	$93.00K	$14.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$59.11M	-$9.763M
YoY Change	-482.02%	-518.65%
Cash From Investing Activities	-$59.21M	-$9.777M
YoY Change	-482.62%	-519.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.52M	$50.92M
YoY Change	-47.99%	-80923.81%
NET CHANGE
Cash From Operating Activities	-14.74M	-$44.80M
Cash From Investing Activities	-59.21M	-$9.777M
Cash From Financing Activities	11.52M	$50.92M
Net Change In Cash	-62.43M	-$3.653M
YoY Change	-1086.08%	-85.59%
FREE CASH FLOW
Cash From Operating Activities	-$14.74M	-$44.80M
Capital Expenditures	$93.00K	$14.00K
Free Cash Flow	-$14.83M	-$44.81M
YoY Change	-52.59%	62.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001437402
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Trading Symbol TradingSymbol	ARDX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36485
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ARDELYX, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1303944
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Fifth Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02451
CY2023Q1	dei	City Area Code CityAreaCode	510
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	745-1700
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	214462429	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92487000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	37886000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	27769000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12120000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7733000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	4823000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	3282000	usd
CY2023Q1	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13835000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13567000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5896000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5112000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	167047000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	153603000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	40124000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25064000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7972000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9295000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1102000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1223000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	774000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	881000	usd
CY2023Q1	us-gaap	Assets Assets	217019000	usd
CY2022Q4	us-gaap	Assets Assets	190066000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10513000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10859000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5074000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7548000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	26880000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	26711000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3998000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3894000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5545000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4211000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11053000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12380000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	63063000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65603000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4814000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5855000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11498000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9025000	usd
CY2023Q1	ardx	Deferred Royalty Obligation Noncurrent DeferredRoyaltyObligationNoncurrent	12223000	usd
CY2022Q4	ardx	Deferred Royalty Obligation Noncurrent DeferredRoyaltyObligationNoncurrent	11254000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Liabilities Liabilities	91598000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	91737000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	214462050	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	214462050	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	198575016	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	198575016	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	21000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	932330000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	878500000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-806910000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-780137000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-54000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	125421000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98329000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	217019000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190066000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11369000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	468000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1537000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	85000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9093000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8851000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26803000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19339000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	37433000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	28275000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26064000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27807000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1028000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	746000	usd
CY2023Q1	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	969000	usd
CY2022Q1	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	0	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1302000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	484000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26759000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28069000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26773000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28071000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207023127	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	207023127	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130934795	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	130934795	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26773000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28071000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	34000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-82000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26739000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28153000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98329000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	138000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50719000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2912000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	34000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26773000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	125421000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	82617000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	83000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5921000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3722000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-82000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28071000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	64190000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26773000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28071000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	-3000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	463000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	902000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	842000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2912000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3722000	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	70000	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	15000	usd
CY2023Q1	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-102000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	710000	usd
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	429000	usd
CY2022Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1044000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	109000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4387000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3892000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16601000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3487000	usd
CY2023Q1	ardx	Increase Decrease In Prepaid Commercial Manufacturing Expense IncreaseDecreaseInPrepaidCommercialManufacturingExpense	268000	usd
CY2022Q1	ardx	Increase Decrease In Prepaid Commercial Manufacturing Expense IncreaseDecreaseInPrepaidCommercialManufacturingExpense	9393000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	774000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9086000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-346000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	753000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2474000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	882000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-937000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-836000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1396000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1041000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3807000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3836000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44795000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27620000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11000000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	27300000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	20763000	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	25763000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	795000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9777000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2332000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	26971000	usd
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2022Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	33038000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50719000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5921000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	200000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	83000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50919000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-63000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3653000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25351000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96140000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72428000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92487000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47077000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	860000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	741000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2023Q1	ardx	Derivative Issued DerivativeIssued	0	usd
CY2022Q1	ardx	Derivative Issued DerivativeIssued	375000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div>
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	130400000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-806900000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92487000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92487000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	37906000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	37886000	usd
CY2023Q1	ardx	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	130393000	usd
CY2023Q1	ardx	Cash Cash Equivalents And Investments Gross Unrealized Gains CashCashEquivalentsAndInvestmentsGrossUnrealizedGains	11000	usd
CY2023Q1	ardx	Cash Cash Equivalents And Investments Gross Unrealized Losses CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses	31000	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	130373000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	27823000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	60000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	27769000	usd
CY2022Q4	ardx	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	123963000	usd
CY2022Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Gains CashCashEquivalentsAndInvestmentsGrossUnrealizedGains	6000	usd
CY2022Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Losses CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses	60000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	123909000	usd
CY2023Q1	ardx	Available For Sale Securities Debt Securities Current Contractual Maturities Maximum AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum	P1Y
CY2022	ardx	Available For Sale Securities Debt Securities Current Contractual Maturities Maximum AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum	P1Y
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	investment
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	investment
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	21702000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22299000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	22566000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5324000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	679000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	723000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	44947000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	28346000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	4823000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	3282000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	40124000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25064000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	44947000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	28346000	usd
CY2023Q1	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13800000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13600000	usd
CY2022Q4	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	2844000	usd
CY2023Q1	ardx	Contract With Customer Gross To Net Sales Provisions ContractWithCustomerGrossToNetSalesProvisions	5760000	usd
CY2023Q1	ardx	Contract With Customer Gross To Credits Or Deductions Issued ContractWithCustomerGrossToCreditsOrDeductionsIssued	-4320000	usd
CY2023Q1	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	4284000	usd
CY2023Q1	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	1000000	usd
CY2023Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	0	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	28861000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1282000	usd
CY2023Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	699000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	26880000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	26880000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7972000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9295000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3998000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3894000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4814000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5855000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8812000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9749000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1064000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1064000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1098000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1058000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3343000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4589000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1321000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	252000	usd
CY2023Q1	ardx	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9505000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	693000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8812000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3998000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4814000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2912000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3722000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13963000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.83
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6472000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.78
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.65
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	56000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.84
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20343000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.18
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9185000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.97
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26773000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28071000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207023000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	207023000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	130935000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130935000	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22991000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17832000	shares
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd

Files In Submission

Name	View Source	Status
ardx-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001628280-23-015212-index-headers.html	Edgar Link	pending
0001628280-23-015212-index.html	Edgar Link	pending
0001628280-23-015212.txt	Edgar Link	pending
0001628280-23-015212-xbrl.zip	Edgar Link	pending
ardx-20230331.htm	Edgar Link	pending
ardx-20230331.xsd	Edgar Link	pending
ardx-20230331xex311.htm	Edgar Link	pending
ardx-20230331xex312.htm	Edgar Link	pending
ardx-20230331xex321.htm	Edgar Link	pending
ardx-20230331_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
ardx-20230331_def.xml	Edgar Link	unprocessable
ardx-20230331_lab.xml	Edgar Link	unprocessable
ardx-20230331_pre.xml	Edgar Link	unprocessable
ardx-20230331_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARDX
ARDELYX, INC. Stock $ardx

2023 Q2 Form 10-Q Financial Statement

#000162828023015212 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX ARDELYX, INC. Stock $ardx

2023 Q2 Form 10-Q Financial Statement

#000162828023015212 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX
ARDELYX, INC. Stock $ardx